Barclays Downgrades Sarepta Therapeutics (SRPT) to Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Citi Opens 90d Downside Catalyst Watch on Sarepta Therapeutics (SRPT)
July 24, 2025 6:46 AM EDTCiti Opens 90d Downside Catalyst Watch on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "We are opening a 90-day downside short-term view on SRPT. Our view is anchored on new and open questions surrounding Elevidys marketing approval in ambulatory Duchenne patients, the possibility of... More
